At any given moment, there are (literally) thousands of analysts poring over hundreds of pages of New Delhi housing starts, Japanese birth rates, and Shanghai's weekly electric consumption figures.
But the real 800 lb gorilla in the room, the single most important demographic in the 21st century continues to fly just below the radar.
I'm talking, of course, about American Women: the healthiest, wealthiest women in human history. If the Golden Rule is "He She who has the gold makes the rules," then the U.S. is a de facto Matriarchy. Women are the primary purchasers of computers, automobiles, banking, financial services and most other big ticket items.
Nevertheless, much of Corporate America is still premised on the male dominated, smoke filled era of AMC's Mad Men, despite the fact that women process information and make purchasing decisions differently from men. Forget the finger pointing and charges of sexism, ignoring women in the 21st Century is a losing financial proposition.
10 Best Japanese Stocks For 2015: TransAtlantic Petroleum Ltd (TAT)
TransAtlantic Petroleum Ltd. is an international oil and gas company engaged in the acquisition, exploration, development and production of crude oil and natural gas. The Company holds interests in developed and undeveloped oil and gas properties in Turkey, Bulgaria and Romania. As of March 1, 2012, it held approximately 5.4 million net onshore acres. As of March 1, 2012, it was producing an aggregate of approximately 2,638 net barrels of oil per day. As of March 1, 2012, it held interests in 57 onshore exploration licenses and nine onshore production leases covering a total of 5.3 million gross acres in Turkey. On February 18, 2011, the Company�� wholly owned subsidiary TransAtlantic Worldwide, Ltd. acquired Direct Petroleum Morocco, Inc. and Anschutz Morocco Corporation and its wholly owned subsidiary TransAtlantic Petroleum Cyprus Limited. On June 7, 2011, TransAtlantic Worldwide acquired Thrace Basin Natural Gas (Turkiye) Corporation. Advisors' Opinion:- [By CRWE]
TransAtlantic Petroleum Ltd. (Amex:TAT) reported that the Turkish Competition Authority has approved the Company’s sale of its oilfield services business to Dalea Partners, LP (“Dalea”, an affiliate of N. Malone Mitchell, 3rd, the Company’s Chairman and Chief Executive Officer).
10 Best Japanese Stocks For 2015: Rimage Corporation(RIMG)
Rimage Corporation provides disc publishing and virtual publishing solutions that enable businesses to deliver digital content to their customers and employees worldwide. Its solutions enable delivery of videos, documents, audio files, and images. The company?s digital publishing solutions archive, distribute, and protect content on CDs, DVDs, and Blu-Ray Discs. It also offers a video platform, which captures, manages, and distributes live and on-demand content. The company, through its joint venture with Taiwan Electronic Data Processing Corporation, also provides Medical Disc System, a medical imaging disc publishing solution. Rimage Corporation was founded in 1978 and is headquartered in Minneapolis, Minnesota.
Advisors' Opinion:- [By ShadowStock]
RIMG: Rimage Corporation (RIMG)
"Helps businesses deliver digital content directly and securely to their customers, employees and partners"
Market Cap: $83.72M
Enterprise Value: $16.93M
Top 10 Diversified Bank Stocks To Buy For 2015: Ardonblue Ventures Inc (ARB)
Ardonblue Ventures Inc., formerly August Metal Corporation, is a Canada-based company engaged in the business of acquiring, exploring and evaluating mineral resource properties. Las Lajas Project consists of approximately seven contiguous mining concessions and is located in Southern Sonora State, Mexico. The concessions are owned by Minera Goldzone SA de CV a wholly owned subsidiary of Goldzone Exploration Inc. Las Lajas has access and infrastructure as it is located approximately 15 kilometers north of the city of Navojoa. The Thurlow Property occupies the central part of the Doratha Morton gold trend, located on British Columbia�� southwestern coast near Phillips Arm. The Property consists of approximately nine crown granted mineral claims covering a total of approximately 142.61hectares. Advisors' Opinion:- [By Rich Duprey]
International media and marketing shop Arbitron� (NYSE: ARB ) �announced yesterday�its second-quarter dividend of $0.10 per share, the same rate it's always paid since 2005
10 Best Japanese Stocks For 2015: SilverSun Technologies Inc (SSNT)
SilverSun Technologies Inc, formerly Trey Resources, Inc., incorporated on October 3, 2002, is a business consultant for small and medium sized businesses and resellers and developers of financial accounting software. It also publishes its own electronic data interchange (EDI) software. It specializes in software integration and deployment, programming, and training and technical support, aimed at improving the financial reporting and operational efficiencies of small and medium sized companies. The sale of its financial accounting software is concentrated in the northeastern United States, while its EDI software and programming services are sold to corporations nationwide. It also provides software customization, data migration, business consulting, and implementation assistance for complex design environments. The Company�� three product categories include Financial Accounting Software, Electronic Data Interchange (EDI) Software and Warehouse Management Systems. Its services include network services and business consulting. In January 2012, the Company acquired the Sage software customer accounts of IncorTech. In January 2012, the Company acquired remaining 20% of SWK Technologies. In April 2012, its subsidiary, SWK Technologies, sold the Sage ERP X3 global enterprise solution to a power generation facility in the Northeastern United States. In June 2012, the Company acquired Micro-Point, Inc. In February 2013, the Company's SWK Technologies, Inc. acquired Sage business partner accounts of Point Solutions, LLC. In February 2013, its wholly owned subsidiary, SWK Technologies Inc., completed the acquisition of the Sage business partner accounts of Colleyville, Texas-based SGEN, LLC (d/b/a Software Generation).
Financial Accounting Software
The Company resells accounting software published by Sage Software, Inc. (Sage) and Intuit, Inc. for the financial accounting requirements of small and medium sized businesses focused on manufacturing and distribution, and the delivery of! related services from the sales of these products, including installation, support and training. These product sales are primarily packaged software programs installed on a user workstation, on a local area network server, or in a hosted environment. The programs perform and support a variety of functions related to accounting, including financial reporting, accounts payable and accounts receivable, and inventory management. The Company provides a variety of services along with its financial accounting software sales. These services include training, technical support, and professional services. It also provides on-site training services that are tailored to meet the needs of a particular customer. It provides end-user technical support services through our support/help desk. Its professional services include project-focused offerings, such as software customization, data migration, and small and medium sized business consulting.
The Company competes with Microsoft.
Electronic Data Interchange (EDI) Software
The Company publishes its own EDI software MAPADOC. The MAPADOC EDI solution is a fully integrated EDI solution that provides users of Sage Software�� MAS family of accounting software products. MAPADOC provides the user with data entry time, elimination of redundant steps, the lowering of paper and postage costs, the reduction of time spent typing, signing, checking and approving documents and the ability to self-manage EDI. The Company markets MAPADOC solutions to its existing and new small and medium-sized business customers, and through a network of resellers.
The Company competes with True Commerce and Kissinger Associates.
Warehouse Management System (WMS)
The Company is a reseller of the Warehouse Management System (WMS) software published by Accellos, Inc. Accellos, Inc. develops warehouse management software for mid-market distributors. The primary purpose of a WMS is to control the movement and storage of mat! erials wi! thin an operation and process the associated transactions. The detailed setup and processing within a WMS can vary from one software vendor to another. The basic WMS uses a combination of item, location, quantity, unit of measure, and order information to determine where to stock, where to pick, and in what sequence to perform these operations. Accellos works as part of a operational solution by integrating seamlessly with RF hardware, accounting software, shipping systems and warehouse automation equipment. The Company markets the Accellos solution to its existing and new medium-sized business customers.
Network Services And Business Consulting
The Company provides network maintenance and service upgrades for its business clients. It provides various services for its clients, including server implementation, support and assistance, operation and maintenance of central systems, technical design of network infrastructure, technical troubleshooting for large scale problems, network and server security, and backup, archiving, and storage of data from servers.
Advisors' Opinion:- [By CRWE]
Today, SSNT has shed (-8.33%) down -0.010 at $.110 with 3,500 shares in play thus far (ref. google finance Delayed: 10:08AM EDT September 12, 2013).
SilverSun Technologies, Inc. previously reported its second quarter results for the three and six months ended June 30, 2013.
Financial highlights for 3 months ended June 30, 2013 compared to 3 months ended june 30, 2012 are as follows. The Company reported revenues increased to $3,870,598, rising 26% from $3,071,425. Software sales climbed 14% to $528,368 from $462,151. Services revenues totaled $3,342,230, increasing 28% from $2,609,264. Income from operations rose to $77,339 from a loss from operations of $319,781. Net income was $62,185, or $0.00 earnings per basic and diluted share, compared to a net loss of $334,031, or 0.00 loss per basic and diluted share.
10 Best Japanese Stocks For 2015: Curtiss-Wright Corporation (CW)
Curtiss-Wright Corporation, together with its subsidiaries, designs, manufactures, and overhauls precision components and systems. It operates in three segments: Flow Control, Motion Control, and Metal Treatment. The Flow Control segment designs, manufactures, and distributes engineered products, including valves, pumps, motors, generators, instrumentation, shipboard systems, and control electronics that manage the flow of liquids and gases, generate power, provide electronic operating systems, and monitor or provide critical functions for naval defense, power generation, oil and gas, and general industrial markets. The Motion Control segment designs, develops, manufactures, and maintains mechanical actuation and drive systems, specialized sensors, motors, electronic controller units, and embedded computing components and control systems for ground defense, aerospace defense, commercial aerospace, and general industrial markets. The Metal Treatment segment provides metallu rgical processing services comprising shot peening, laser peening, specialty coatings and heat treating for commercial and defense aerospace, oil and gas, power generation, automotive, transportation, construction equipment, and miscellaneous metal working industries. The company operates primarily in the United States, the United Kingdom, and Canada. Curtiss-Wright Corporation was founded in 1929 and is headquartered in Parsippany, New Jersey.
Advisors' Opinion:- [By Shauna O'Brien]
On Monday, Curtiss-Wright Corp. (CW) announced that it has completed its acquisition of Arens Controls, LLC for $98 million.
The newly acquired business will operate under CW’s Controls segment. David C. Adams, President and CEO of CW noted: “The acquisition of Arens complements our previous acquisitions of Williams Controls and PG Drives, further strengthening and growing Curtiss-Wright’s existing industrial controls business.”
“This is another step toward our vision of being the supplier of choice for operator control subsystems and critical drivetrain components in specialty vehicles. As a leading designer and manufacturer of critical vehicle controls technologies, Arens’ complementary products and long-standing customer relationships position Curtiss-Wright for increased penetration within the commercial and off-road vehicle markets. Additionally, this acquisition allows us to leverage our global manufacturing footprint to create margin expansion opportunities,” Adams added.
Curtiss-Wright shares were down 46 cents, or 1.00%, during Monday morning trading. The stock is up 39% YTD.
10 Best Japanese Stocks For 2015: iShares Cohen & Steers REIT ETF (ICF)
iShares Cohen & Steers Realty Majors Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Cohen & Steers Realty Majors Index (the Index). The Index consists of selected real estate investment trusts (REITs). The objective of the Index is to represent relatively large and liquid REITs that may benefit from future consolidation and securitization of the United States real estate industry. The Index is modified capitalization-weighted with constituent companies having a maximum index weight of 8%.
The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Barclays Global Fund Advisors is the investment advisor of the Fund.
Advisors' Opinion:- [By Matthew McCall]
The SPDR Utilities ETF (NYSE: XLU) is up 1.5 percent today and is breaking to a one-month high. The iShares Cohen & Steers Realty ETF (NYSE: ICF), which owns a basket of REITs, is up 1.1 percent, also looking for a one-month high.
10 Best Japanese Stocks For 2015: Salix Pharmaceuticals Ltd (SLXP)
Salix Pharmaceuticals, Ltd., incorporated on December 31, 2001, is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. As of December 31, 2012, the Company�� products included XIFAXAN, MOVIPREP, APRISO, RELISTOR, OSMOPREP, SOLESTA, DEFLUX, FULYZAQ, GIAZO, METOZOLV ODT, AZASAN, ANUSOL-HC, PROCTOCORT, PEPCID, DIURIL and COLAZAL. As of December 31, 2012, its primary product candidates under development included Rifaximin, Methylnaltrexone bromide oral, Budesonide foam and Rifaximin EIR. In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.
Xifaxan (rifaximin) tablets
Xifaxan is a gastrointestinal-specific oral antibiotic. The Food and Drug Administration ( FDA) approved Xifaxan 200 milligram for the treatment of patients 12 years of age and older with travelers��diarrhea caused by noninvasive strains of E coli. Xifaxan 550 milligram was approved by the FDA for reduction in risk of overt hepatic encephalopathy (HE), recurrence in patients 18 years of age or older.
It launched Xifaxan 200milligram in the United States and Xifaxan 550 milligram using its own direct sales force. The Company is exploring potential additional indications, formulations, clinical trials and co-promotion arrangements to capitalize on the potential for Xifaxan, including its development program in irritable bowel syndrome.
In October 2012, the USPTO declared an interference action to determine the priority of invention between Cipla�� application related to amorphous rifaximin and Solmag SpA�� application directed to amorphous rifaximin. In February 2012, the FDA posted draft bioequivalence guidance for rifaximin 550 milligram tablets. The draft guidance for rifaximin 550 milligram tablets recommends that in addition to conducting the program outlined in the FDA posted ! draft guidance document for rifaximin 200 milligram tablets discussed above, a single-dose, three-way crossover in-vivo study of fasting bioequivalence with pharmacokinetic endpoints in both fasting and fed states be performed in the 550 milligram tablets. Additionally, the guidance stipulated that the formulation of the 550 milligram strength should be proportionally similar to that of the 200 milligram strength in order to file an ANDA for approval of a generic rifaximin 550 milligram tablet for the treatment of hepatic encephalopathy.
MoviPrep (PEG 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid) oral solution
MoviPrep is a patent-protected, liquid polyethylene glycol-salt, or PEG, bowel cleansing product that the FDA approved. MoviPrep is indicated for bowel cleansing prior to colonoscopy, intestinal surgery and barium enema X-ray examinations.
Apriso (mesalamine) extended-release capsules 0.375 gram
Apriso is a locally-acting aminosalicylate and is the only delayed and extended release mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Apriso is designed to provide for the distribution of the active ingredient beginning in the small bowel and continuing throughout the colon. The product�� prolonged release mechanism might allow them to expand the range of treatment options for ulcerative colitis.
Relistor (methylnaltrexone bromide)
Relistor Subcutaneous Injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Relistor is approved for use in over 55 countries worldwide.
OsmoPrep and Visicol (sodium phosphate monobasic monohydrate, USP, sodium phosphate dibasic anhydrous, USP) tablets
Visicol and OsmoPrep tablets are indicated for clean! sing of t! he colon as a preparation for colonoscopy in adults 18 years of age or older. Visicol and OsmoPrep are the only, tablet bowel cleansing products approved by the FDA and marketed in the United States. OsmoPrep is a patented, second-generation tablet bowel cleansing product that the FDA approved. OsmoPrep offers potential benefits compared to Visico,l such as its lack of microcrystalline cellulose, smaller tablet size and possible lower dose administration.
Solesta
Solesta is a biocompatible tissue bulking agent, consisting of dextranomer microspheres and stabilized sodium hyaluronate. Solesta is indicated for the treatment of fecal incontinence in patients 18 years and older who have failed conservative therapy, such as diet, fiber therapy and/or anti-motility medications. It is the only injectable gel for this indication to be administered in an outpatient setting without the need for surgery or anesthesia.
Deflux
Deflux is a medical device indicated for children affected by Grades II-IV vesicoureteral reflux, a malformation of the urinary bladder that can result in severe infections of the kidneys and irreversible kidney damage. Deflux was granted premarket approval application (PMA) approval, and has been on the market in the United States.
Fulyzaq (crofelemer) delayed-release tablets
On December 31, 2012, the FDA granted marketing approval for this product, under the trade name Fulyzaq. Fulyzaq is indicated for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. Fulyzaq should also be eligible for five years of marketing exclusivity from the date of FDA approval, and the product might be entitled to patent term restoration.
Giazo (balsalazide disodium) tablets
February 3, 2012, the FDA granted marketing approval for this product under the trade name Giazo. Giazo is indicated for the treatment of mildly to moderately active ulcerative col! itis in m! ale patients 18 years of age and older. It shipped Giazo to wholesalers in 2012.
Metozolv ODT (metoclopramide hydrochloride) 5 milligrams and 10 milligrams orally disintegrating tablets
METOZOLV ODT is indicated for the relief of symptomatic gastroesophageal reflux or short-term (4-12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy and diabetic gastroparesis or the relief of symptoms in adults associated with acute and recurrent diabetic gastroparesis.
Azasan (azathioprine) tablets
Azasan is an FDA-approved drug that suppresses immune system responses and is indicated for preventing rejection of kidney transplants and treatment of severe arthritis. It launched the 75 and 100 milligrams dosage strengths of Azasan in the United States.
Anusol-HC and Proctocort (hydrocortisone) creams and suppositories
The Company acquired the right to sell Anusol-HC 2.5% (hydrocortisone USP) cream, Anusol-HC 25 milligrams (hydrocortisone acetate) rectal suppositories, Proctocort 1% (hydrocortisone USP) cream and Proctocort 30 mg (hydrocortisone acetate) rectal suppositories from King Pharmaceuticals, Inc. The two cream products are topical corticosteroids indicated for relief of the inflammatory and pruritic, or itching, manifestations of corticosteroid-responsive dermatoses. The two suppository products are indicated for use in inflamed hemorrhoids and postirradiation proctitis, as well as an adjunct in the treatment of chronic ulcerative colitis and other inflammatory conditions.
Pepcid (famotidine) for Oral Suspension and Diuril (Chlorothiazide)
Pepcid Oral Suspension is a widely known prescription pharmaceutical product indicated for several gastrointestinal indications, including the treatment of duodenal ulcer, benign gastric ulcer and gastro-esophageal reflux disease. Pepcid Oral Suspension and Diuril Oral Suspension, both liquid form! ulations ! of their solid dosage form counterparts, compete in a combined annual United States market concentrated in pediatric and hospitalized patient populations.
Colazal (balsalazide disodium) capsules
The Company launched Colazal to physicians in the United States. FDA approved Colazal for use in pediatric patients between 5 to 17 years of age with ulcerative colitis. The pediatric use of Colazal has been granted orphan drug designation. The Office of Generic Drugs, or OGD, approved three generic balsalazide capsule products.
The Company competes with GlaxoSmithKline plc, Giuliani S.p.A., Axcan Pharma, Inc., Abbott Laboratories, Warner Chilcott plc, Shire Pharmaceuticals Group plc, Pharmacia & Upjohn, Inc., Alaven Pharmaceutical LLC, Ferring Pharmaceuticals, Inc, Takeda Pharmaceutical Company Limited, Cumberland Pharmaceuticals, Inc, Prometheus Laboratories, Inc., Ranbaxy Pharmaceuticals, Ferndale Laboratories, GATE Pharmaceuticals , Nycomed , Medtronic, Inc., and Cubist Pharmaceuticals, Inc.
Advisors' Opinion:- [By Garrett Cook]
Salix Pharmaceuticals (NASDAQ: SLXP) shares shot up 5.52 percent to $168.66 on report of takeover talks with Allergan. Allergan (NYSE: AGN) is set to acquire Salix Pharmaceuticals in a deal probably worth more than $10 billion, according to Dow Jones Newswires.
- [By Garrett Cook]
Salix Pharmaceuticals (NASDAQ: SLXP) shares tumbled 3.96 percent to $131.84 after the company agreed to merge with a unit of Cosmo Pharmaceuticals SpA.
- [By Garrett Cook]
Salix Pharmaceuticals (NASDAQ: SLXP) shares tumbled 3.01 percent to $133.15 after the company agreed to merge with a unit of Cosmo Pharmaceuticals SpA.
10 Best Japanese Stocks For 2015: Assa Abloy AB (ASAZY.PK)
Assa Abloy AB is a Sweden-based company engaged in the secure door opening solutions. It is organized into five divisions: Europe, Middle East and Africa (EMEA), North and South America (Americas), Asia, Australia and New Zealand (Asia Pacific), Global Technologies and Entrance Systems. The EMEA, Americas and Asia Pacific divisions manufacture mechanical and electromechanical locks, security doors and hardware in their respective geographical markets. The Global Technologies division operates in the product areas of access control systems, secure card issuance, identification technology and hotel locks. The Entrance Systems division is a supplier of entrance automation products and services. The Company�� subsidiaries include ASSA Sverige AB, Timelox AB and ABLOY Holdings Ltd., among others. In November 2013, it acquired Ameristar Fence Products Inc, a manufacturer of ornamental fences and gates. In January 2014, it acquired IdenTrust. In February 2014, it acquired Lumidigm. Advisors' Opinion:- [By Weighing Machine]
Domiciled in Sweden, Assa Abloy (ASAZY.PK) is the largest lock maker in the world with a global market share of nearly 12%. While the construction market has been difficult since the financial crisis, Assa has continued to increase revenue and operating profit every year since 2010 and is on track to do so again in 2013. While commercial construction has been subdued, the aftermarket (which represents ~70% of the total lock market) is driven by changes in tenancy, renovation, and extensions have not been very cyclical and provides the company with a steady stream of profits. Assa has been cobbled together through 150+ acquisitions since the early 1990s and while management has done a good job of rationalizing facilities, there remain opportunities to increase manufacturing efficiencies. Similarly, the company's back office is still running dozens of IT systems (as a result of acquisitions) but management plans to consolidate these over the next few years. Further, Assa remains an active consolidator of the locks industry - it should be able to add 5% per year to sales via acquisitions (as an aside, those interested in micro-caps should have a look at Securidev in France which trades at less than half the private market value Assa has paid for lock makers on average over the past decade). Having the highest margins in the industry, Assa is able to achieve significant synergies on acquired businesses and earn good returns on capital for its shareholders through M&A. Thus even in a difficult economy, we expect Assa will continue to grow its operating profit given its steady after market revenue, opportunity to improve results through cost cutting, and through value accretive M&A. While its shares are not cheap, at 19x earnings, shares could offer investors with a five year holding period and an 8-10% annualized return.
10 Best Japanese Stocks For 2015: Senesco Technologies Inc (SNTI)
Senesco Technologies, Inc., incorporated on September 30. 1999, is engaged in utilize its eukaryotic translation initiation Factor 5A, or Factor 5A, and deoxyhypusine synthase (DHS), and related technologies for human therapeutic applications to develop approaches to treat cancer and inflammatory diseases. In agricultural applications, the Company has licensed applications of the Factor 5A, DHS and Lipase platforms to develop the productivity of fruits, flowers, vegetables, agronomic and biofuel feedstock crops through the control of cell death and growth in plants.
Human Therapeutic Applications
The Company has developed a therapeutic candidate, SNS01-T, an improved formulation of SNS01, for the potential treatment of multiple myeloma and non-Hodgkin B-cell lymplomas. SNS01-T utilizes the Company's Factor 5A technology and consists of two components, which include a DNA plasmid (pDNA), expressing human eIF5A containing a lysine to arginine substitution at amino acid position 50, (eIF5AK50R), and a small inhibitory RNA (siRNA). These two components are combined in a fixed ratio with a polymer, polyethyleneimine (PEI), which enables self-assembly of the DNA and RNA into nanoparticles with demonstrated enhanced delivery to tissues and protection from degradation in the blood stream. The Company has also demonstrated that the combination of lenalidomide and SNS 01-T performs better than either treatment alone in mouses xenograft models of human mantle cell lymphoma. The Company's human therapeutic research program, which consists of pre-clinical in-vitro and in-vivo experiments designed to assess the role and mode of action of Factor 5A in human diseases and a phase 1a/2b clinical trial.
The Company competes with Celgene, Inc., Takeda/Millennium, ONYX Pharmaceuticals, Inc., Amgen Inc., Janssen Biotech, Inc., Novartis AG, and Pharmacyclics, Inc.
Agricultural Applications
The Company's agricultural research focuses on the discovery and develo! pment of certain gene technologies, which are designed to confer positive traits on fruits, flowers, vegetables, forestry species and agronomic crops. The Company's research and development initiatives for agriculture include develop and implement the DHS and Factor 5A gene technology in banana, canola, cotton, turfgrass, rice, alfalfa, corn, soybean and trees; and test the resultant crops for new beneficial traits such as increased yield, increased tolerance to environmental stress, disease resistance and more efficient use of fertilizer.
The Company competes with Mendel Biotechnology, Renessen LLC, Exelixis Plant Sciences, Inc., and Syngenta International AG.
Advisors' Opinion:- [By Peter Graham]
At the end of last week, small cap stocks Senesco Technologies, Inc (OTCBB: SNTI), VolitionRX Ltd (OTCMKTS: VNRX) and Micromem Technologies Inc (OTCBB: MMTIF) were all trending upwards ��ending up 13.65%, 8.73% and 7.61%, respectively, on Friday. However, it�� a new trading week with the last two trading days for the year. So what direction will these three small caps head in for the end of this year and into next year? Here is a quick look to help you decide on a trading or investment strategy:
10 Best Japanese Stocks For 2015: NetSol Technologies Inc.(NTWK)
Netsol Technologies, Inc. designs, develops, and markets software products for the automobile finance and leasing, banking, healthcare, and financial services industries worldwide. It offers NetSol Financial Suite, which is an end-to-end solution that covers the leasing and finance cycle. The NetSol Financial Suite consist of software applications comprising Point of Sale, a front office processing system for the finance sector; Credit Application Processing System to handle the incoming credit applications from dealers, agents, brokers, and the direct sales force; Contract Management System to manage and maintain a contract; Wholesale Finance System to automate and manage the floor plan/bailment activities of dealerships; and Fleet Management System to handle fleet management needs. The NetSol Financial Suite also includes LeasePak that develops Web-enabled and Web-based tools for the leasing technology industry. In addition, the company offers LeaseSoft Portals and Modul es; enterprise wide information systems, such as LRMIS, MTMIS, and Hospital Management Systems; accounting outsourcing services; and career and technology programs. Further, it provides portfolio management systems for the financial services industry; and consulting, custom development, systems integration, and technical services for the healthcare, insurance, real estate, and technology markets. Additionally, the company offers business intelligence, independent system review, information security, and software process improvement consulting services; maintenance and support, and project management services; and solutions for the defense and military forces. It serves Fortune 500 manufacturers, automakers, financial institutions, utilities, technology providers, and government agencies. The company was formerly known as NetSol International, Inc. and changed its name to NetSol Technologies, Inc. in March 2002. NetSol Technologies, Inc. was founded in 1997 and is based in Ca labasas, California.
Advisors' Opinion:- [By CRWE]
NetSol Technologies (Nasdaq:NTWK), a provider of global IT and enterprise application solutions, reported that Mercedes-Benz Leasing Company Ltd. (China), went live with the NetSol Financial Suite (NFS(tm)).
- [By Roberto Pedone]
Another under-$10 stock that's quickly pushing within range of triggering a near-term breakout trade is Netsol Technologies (NTWK), which designs, develops, markets and exports proprietary software products to customers in the automobile finance and leasing, banking, health care and financial services industries internationally. This stock is off to a strong start in 2013, with shares up by 28%.
If you take a look at the chart for Netsol Technologies, you'll notice that this stock has been downtrending badly for the last two months, with shares sliding sharply lower from its high of $12.10 to its recent low of $7.03 a share. During that downtrend, shares of NTWK have been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of NTWK have started to stabilize and reverse its downtrend, since the stock has started to make higher lows and higher highs over the last few weeks. This move is quickly pushing shares of NTWK within range of triggering a near-term breakout trade.
Market players should now look for long-biased trades in NTWK if it manages to break out above some near-term overhead resistance at $7.74 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average action of 225,909 shares. If that breakout hits soon, then NTWK will set up to re-test or possibly take out its next major overhead resistance levels at $8.71 to its 50-day moving average at $9.16 a share. Any high-volume move above those levels will then give NTWK a chance to tag its 200-day at $10.20 to more resistance at $10.45 a share.
Traders can look to buy NTWK off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $7.20 or $7.03 a share. One can also buy NTWK off strength once it clears $7.74 a share with volume and then simply use a stop that sits a comfortable percentage fr
No comments:
Post a Comment